Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.

NCT07108998 is registered in ClinicalTrials.gov with Zulfa Omer as lead sponsor.

NCT NCT07108998
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07108998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.
Lead sponsor
Zulfa Omer
Phase
Phase 2
Overall status
Recruiting
Start date
August 22, 2025
Completion date
July 1, 2029
Enrollment
22 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, chronic lymphocytic leukemia variants, cll, cll/sll, sll, small lymphocytic lymphoma, small lymphocytic lymphoma variant